Services
EnquBio's Comprehensive Drug Discovery Solutions & Services
At EnquBio, our expert team delivers high quality, efficient, and dependable R&D solutions that enable pharmaceutical and biotech partners to advance and expand their drug development pipelines.
- Discovery Biology
- Plate-Based Pharmacology
- Immunology
- Ex Vivo Pharmacology
-
In Vivo Pharmacology
- Inflammation & Autoimmune Diseases Models
- Syngeneic and Cell Line-Derived Xenograft (CDX) Models
- Humanized Immuno-Oncology Models
- FLI and BLI based optical in vivo imaging for orthotopic models and drug biodistribution
- Pharmacokinetic and Pharmacodynamic (PK/PD)
- Non-GLP Toxicology
- Other In Vivo Efficacy Models
- Biomarker & Bioanalysis
Ex Vivo Tumor Pharmacology
EnquBio supports short-term ex vivo tumor pharmacology using xenograft-derived and fresh human tumor tissue. Customized studies combine controlled compound exposure with functional, cellular, protein and molecular readouts to investigate pharmacodynamic response, pathway modulation and mechanism of action in a tissue-relevant setting.
Why Ex Vivo Tumor Pharmacology?
Tumor response is shaped by more than cancer cells alone. Short-term explant and tumor-fragment studies can retain important features of the original tissue architecture and multicellular environment while enabling controlled drug exposure ex vivo.
Preserve more of the native tumor environment
Evaluate pharmacology in intact or minimally disrupted tumor material rather than isolated cancer cells alone.
Connect response with pharmacodynamic biology
Pair treatment effects with signaling, target modulation, cytokine, cellular and molecular endpoints.
Bridge controlled models and human tissue
Use xenograft-derived tumors for controlled study development and fresh human tissue for translational investigation.
Study Formats
Study format is selected around tissue source, biological question, available material and downstream endpoints.
Xenograft-Derived Tumor Explants
Tumors harvested from established CDX studies can be carried into short-term ex vivo compound testing and mechanistic analysis. This format is especially useful when ex vivo findings need to be interpreted alongside matched in vivo efficacy or PK/PD data.
- Short-term compound exposure
- Dose and time-response studies
- Pathway and target modulation
- Matched in vivo–ex vivo study designs
Fresh Human Tumor Tissue
Fresh human tumor tissue can be incorporated into customized feasibility and exploratory pharmacology studies. Depending on tissue quality and available material, studies may use intact fragments, explant-style cultures or dissociated tumor-derived cell preparations.
- Short-term drug-response studies
- Tumor and stromal biomarker assessment
- Immune and cellular characterization
- Integrated protein and molecular readouts
Questions These Studies Can Address
The study starts with the pharmacology question, not a fixed assay format.
Does the compound modulate its intended pathway?
Measure target engagement, phosphoprotein changes, protein degradation or other pharmacodynamic endpoints.
Does the tissue show a treatment response?
Assess viability, apoptosis, proliferation or other response-associated changes over a defined treatment window.
How does the tumor microenvironment respond?
Characterize immune, stromal or soluble biomarker changes where tissue quality and model format support those analyses.
Do ex vivo findings align with in vivo pharmacology?
Compare pathway and biomarker responses with matched efficacy and PK/PD data from the originating tumor model.
Which conditions are worth advancing?
Explore dose, exposure time, combinations or sequencing before larger in vivo studies.
Which biomarkers best capture drug activity?
Combine cellular, protein and molecular endpoints to identify informative pharmacodynamic readouts.
Typical Study Workflow
A fit-for-purpose workflow from tissue receipt to integrated interpretation.
Tissue Collection / Receipt
Fresh xenograft or human tumor tissue enters the study workflow.
Baseline Assessment
Review tissue condition, available material and study suitability.
Explant Preparation
Prepare fragments or another fit-for-purpose tumor format.
Compound Treatment
Apply vehicle, reference and test conditions across dose and time.
Endpoint Analysis
Measure functional, cellular, protein and molecular responses.
Integrated Interpretation
Interpret pharmacology in the context of model, treatment and study objective.
Integrated Readouts
Pair tumor pharmacology with EnquBio's existing biomarker platforms to characterize response across multiple biological levels.
Extend an In Vivo Study Ex Vivo
Tumors generated within EnquBio's in vivo oncology programs can be carried directly into downstream ex vivo pharmacology and biomarker analysis.
Why EnquBio
A tumor pharmacology program can be integrated with the in vivo and biomarker capabilities already available within one team.
Planning an ex vivo tumor study?
Share your tumor source, compound mechanism, available tissue and key biological question. Our scientists can help define a fit-for-purpose study strategy and prioritize the most informative readouts.
Contact Our Scientists →